Who’s Developing What in New Cancer Drugs 2005?
Research and Markets (http://www.researchandmarkets.com/reports/c24675) has announced the addition of Who’s Developing What in New Cancer Drugs 2005? to their offering.
Over 1,200-pages analysing the structure, performance and research of over 135 leading cancer drug development companies.
Cancer continues to dominate industry research and investment as the search for really effective therapies hots up. The commercial rewards for companies that make significant breakthroughs in the cure or control of key cancers such as breast, ovarian, lung and prostate are considerable.
The application of biotechnology to the identification and development of drug candidates has seen a range of novel paths pursued by a number of development companies.
For analysts, investors and pharmaceutical company executives, being able to readily and easily assess these companies, the research they are pursuing, products being developed, collaborators and financial performance/funding is key to understanding this sector of the market.
That is why the new 4th edition of this respected management report, Who’s Developing What in New Cancer Drugs 2005? is the essential reference work for everyone in the field. The report covers more than 135 companies — from the largest blue-chip multinational to smaller specialist organisations — and all phases of development from research to launched products.
For each company you can evaluate:
— Summary: At a glance review of agreements, products and R&D pipeline.
— Overview: Background, technology and research techniques they have developed for drug discovery.
— Agreements: Key details of who the company is collaborating with, and on what.
— Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
— R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
— Financials: An analysis of financial performance including P&L, R&D expenditure and funding.
The following are a selection of the 135 companies profiled in the report:
— Active Biotech
— Alfacell
— Amgen
— AntiCancer
— Antisoma
— Ark Therapeutics
— AstraZeneca
— Bayer
— Biomira
— BioVex
— Bristol-Myers Squibb
— Can-Fite BioPharma
— CancerVax
— Celgene
— Cephalon
— Chiron
— Clavis Pharma
— Daiichi
— Dendreon
— Eli Lilly
— Endocyte
— Favrille
— Genzyme Oncology
— GlaxoSmithKline
— GPC Biotech
— Immunomedics
— Intarcia Therapeutics
— Ligand Pharmaceuticals
— Lorus Therapeutics
— MediGene
— MedImmune
— Merck
— Novartis
— OSI Pharmaceuticals
— Oxford BioMedica
— OXiGENE
— Pfizer
— Roche
— Sanofi-aventis
— Schering-Plough
— Synta Pharmaceuticals
— Telik
— Transgene
— Xenova
For more information visit http://www.researchandmarkets.com/reports/c24675.